NPM1 is the most frequently mutated gene in AML, along with FLT3 and DNMT3A; specifically, the NPM1 mutation occurs in about 30% of de novo AML cases [5] and defines a distinct AML subgroup with a favorable prognosis [50]. This evidence concerns the gene FLT3 and acute myeloid leukemia.